Skip to contentC
Cerenome, Inc.
C
CNSYCerenome, Inc. Q3 2025 · 10-Q
Revenue$1.40M$1.40M−4.1% vs Q3 2024 Net Income-$4.42M-$4.42MN/M vs Q3 2024 EPS Diluted-$0.04-$0.04N/M vs Q3 2024 Operating Income-$4,482,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cerenome, Inc. · CIK 1095981 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$2,575,000N/M Margins · derivedOperating margin-320.8%−59.9 pt vs Q3 2024
Net margin-316.6%−119.2 pt vs Q3 2024
ended Sep 30, 2025 · filed Oct 30, 2025 · 30 d after period end